{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T03:03:54Z","timestamp":1779764634501,"version":"3.53.1"},"reference-count":89,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Isotretinoin, a potent retinoid, is highly effective in the treatment of severe acne vulgaris. Its nearly 60-year history began with the Swiss pharmaceutical company La Roche in the 1960s, where it was initially studied for potential benefits in cancer treatment. This article delineates the historical trajectory of isotretinoin from early clinical trials in the 1970s and 1980s, highlighting its efficacy and safety profile, leading to US Food and Drug Administration approval in 1982. The review also addresses contemporary concerns such as the drug\u2019s teratogenicity and potential link to depression and provides an overview of regulatory measures and mixed research findings on mental health and sexual dysfunction. The current status of isotretinoin in other medical areas, including its exploration as a chemotherapy adjunct, is examined.<\/jats:p>","DOI":"10.1093\/ced\/llaf523","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:57:40Z","timestamp":1764075460000},"page":"939-950","source":"Crossref","is-referenced-by-count":0,"title":["The history, development and current status of isotretinoin: a review article"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1999-9562","authenticated-orcid":false,"given":"Attam","family":"Khan","sequence":"first","affiliation":[{"name":"Mater Misericordiae University Hospital, Phibsborough , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corniche","family":"Khan","sequence":"additional","affiliation":[{"name":"Dermatology Department, NHS Lothian, Lauriston Building , Edinburgh ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saim","family":"Ahmed","sequence":"additional","affiliation":[{"name":"University Hospital Limerick, Dooradoyle , Limerick ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"2026052522572018500_llaf523-B1","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1067\/mjd.2001.113714","article-title":"Cellular metabolism and actions of 13-cis-retinoic acid","volume":"45","author":"Blaner","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0190-9622(83)80143-1","article-title":"The development of retinoids in experimental and clinical oncology","volume":"9","author":"Bollag","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B3","first-page":"1332","article-title":"Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)","volume":"35","author":"Sporn","year":"1976","journal-title":"Fed Proc"},{"key":"2026052522572018500_llaf523-B4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM197902153000701","article-title":"Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid","volume":"300","author":"Peck","year":"1979","journal-title":"N Engl J Med"},{"key":"2026052522572018500_llaf523-B5","volume-title":"Acne Vulgaris","author":"Sutaria","year":"2023"},{"key":"2026052522572018500_llaf523-B6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF00406424","article-title":"Inhibitory effects of 13-cis-retinoic acid on human sebaceous glands","volume":"269","author":"Landthaler","year":"1980","journal-title":"Arch Dermatol Res"},{"key":"2026052522572018500_llaf523-B7","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/sj.jid.5700289","article-title":"13-cis retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes","volume":"126","author":"Nelson","year":"2006","journal-title":"J Invest Dermatol"},{"key":"2026052522572018500_llaf523-B8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1523-1747.2000.00066.x","article-title":"13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors","volume":"115","author":"Tsukada","year":"2000","journal-title":"J Invest Dermatol"},{"key":"2026052522572018500_llaf523-B9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/1523-1747.ep12259164","article-title":"Cellular retinoic acid-binding proteins in human epidermis and sebaceous follicles","volume":"82","author":"Puhvel","year":"1984","journal-title":"J Invest Dermatol"},{"key":"2026052522572018500_llaf523-B10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4161\/derm.15331","article-title":"Isotretinoin and FoxO1: a scientific hypothesis","volume":"3","author":"Melnik","year":"2011","journal-title":"Dermatoendocrinol"},{"key":"2026052522572018500_llaf523-B11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2133.2011.10392.x","article-title":"TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells","volume":"165","author":"Nelson","year":"2011","journal-title":"Br J Dermatol"},{"key":"2026052522572018500_llaf523-B12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12967-017-1297-2","article-title":"p53: key conductor of all anti-acne therapies","volume":"15","author":"Melnik","year":"2017","journal-title":"J Transl Med"},{"key":"2026052522572018500_llaf523-B13","first-page":"1355","article-title":"Isotretinoin treatment upregulates the expression of p53 in the skin and sebaceous glands of patients with acne vulgaris","volume":"315","author":"Agamia","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2026052522572018500_llaf523-B14","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1172\/JCI33869","article-title":"Neutrophil gelatinase-\u00adassociated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells","volume":"118","author":"Nelson","year":"2008","journal-title":"J Clin Invest"},{"key":"2026052522572018500_llaf523-B15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2133.2011.10362.x","article-title":"Isotretinoin increases skin-surface levels of neutrophil gelatinase-associated lipocalin in patients treated for severe acne","volume":"165","author":"Lumsden","year":"2011","journal-title":"Br J Dermatol"},{"key":"2026052522572018500_llaf523-B16","doi-asserted-by":"crossref","first-page":"e13044","DOI":"10.1111\/dth.13044","article-title":"Plasma dermcidin levels in acne patients, and the effect of isotretinoin treatment on dermcidin levels","volume":"32","author":"Alatas","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026052522572018500_llaf523-B17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/1523-1747.ep12471782","article-title":"Effects of 13-cis retinoic acid, all-trans-retinoic acid, and acitretin on the proliferation, lipid synthesis and keratin expression of cultured human sebocytes in vitro","volume":"96","author":"Zouboulis","year":"1991","journal-title":"J Invest Dermatol"},{"key":"2026052522572018500_llaf523-B18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0625.1994.tb00271.x","article-title":"Progressive differentiation of human sebocytes in vitro is characterized by increasing cell size and altering antigen expression and is regulated by culture duration and retinoids","volume":"3","author":"Zouboulis","year":"1994","journal-title":"Exp Dermatol"},{"key":"2026052522572018500_llaf523-B19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2133.1993.tb00165.x","article-title":"Isolation and maintenance of the human pilosebaceous duct: 13-cis retinoic acid acts directly on the duct in vitro","volume":"128","author":"Guy","year":"1993","journal-title":"Br J Dermatol"},{"key":"2026052522572018500_llaf523-B20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/archderm.1988.01670040042019","article-title":"Effect of isotretinoin on serum levels of precursor and peripherally derived\u00a0androgens in patients with acne","volume":"124","author":"Lookingbill","year":"1988","journal-title":"Arch Dermatol"},{"key":"2026052522572018500_llaf523-B21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0625.1994.tb00271.x","article-title":"Progressive differentiation of human sebocytes in vitro is characterized by increasing cell size and altering antigen expression and is regulated by culture duration and retinoids","volume":"3","author":"Zouboulis","year":"1994","journal-title":"Exp Dermatol"},{"key":"2026052522572018500_llaf523-B22","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.3390\/cells12222600","article-title":"Acne transcriptomics: fundamentals of acne pathogenesis and isotretinoin treatment","volume":"12","author":"Melnik","year":"2023","journal-title":"Cells"},{"key":"2026052522572018500_llaf523-B23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1126\/science.910158","article-title":"13-cis-retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine","volume":"198","author":"Grubbs","year":"1977","journal-title":"Science"},{"key":"2026052522572018500_llaf523-B24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ijc.2910170311","article-title":"The influence of vitamin A on the susceptibility of the rat lung to 3-methylcholanthrene","volume":"17","author":"Nettesheim","year":"1976","journal-title":"Int J Cancer"},{"key":"2026052522572018500_llaf523-B25","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/jnci\/60.6.1489","article-title":"Dose response to intrarectal administration of N-methyl-N-nitrosourea and histopathologic evaluation of the effect of two retinoids on colon lesions induced in rats","volume":"60","author":"Ward","year":"1978","journal-title":"J Natl Cancer Inst"},{"issue":"4 Pt 2 Suppl","key":"2026052522572018500_llaf523-B26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0190-9622(82)70063-5","article-title":"Isotretinoin versus placebo in the treatment of cystic acne: a randomized double-blind study","volume":"6","author":"Peck","year":"1982","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B27","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(80)92273-4","article-title":"13-cis retinoic acid and acne","volume":"316","author":"Jones","year":"1980","journal-title":"Lancet"},{"key":"2026052522572018500_llaf523-B28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0190-9622(80)80074-0","article-title":"The treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum production and the clinical response in a multiple-dose trial","volume":"3","author":"Farrell","year":"1980","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2133.1982.tb00410.x","article-title":"A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population","volume":"107","author":"King","year":"1982","journal-title":"Br J Dermatol"},{"key":"2026052522572018500_llaf523-B30","first-page":"299","article-title":"Dose\u2013response relationship in isotretinoin therapy for conglobate acne","volume":"167","author":"van der Meeren","year":"1983","journal-title":"Dermatologica"},{"key":"2026052522572018500_llaf523-B31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2133.1983.tb03973.x","article-title":"A dose\u2013response study of I3-cis-retinoic acid in acne vulgaris","volume":"108","author":"Jones","year":"1983","journal-title":"Br J Dermatol"},{"key":"2026052522572018500_llaf523-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000364860","article-title":"Acne pathogenesis: history of concepts","volume":"229","author":"Tilles","year":"2014","journal-title":"Dermatology"},{"key":"2026052522572018500_llaf523-B33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-4362.1985.tb05775.x","article-title":"Isotretinoin and tetracycline in the management of severe nodulocystic acne","volume":"24","author":"Lester","year":"1985","journal-title":"Int J Dermatol"},{"key":"2026052522572018500_llaf523-B34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0190-9622(87)70200-X","article-title":"Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation","volume":"17","author":"Chalker","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2230.1992.tb00196.x","article-title":"A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne","volume":"17","author":"Hughes","year":"1992","journal-title":"Clin Exp Dermatol"},{"key":"2026052522572018500_llaf523-B36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/archderm.1991.01680030061007","article-title":"An observational study of isotretinoin recipients treated for acne in a health maintenance organization","volume":"127","author":"McElwee","year":"1991","journal-title":"Arch Dermatol"},{"key":"2026052522572018500_llaf523-B37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0163-7258(89)90080-6","article-title":"Bone changes associated with oral retinoid therapy","volume":"40","author":"White","year":"1989","journal-title":"Pharmacol Ther"},{"key":"2026052522572018500_llaf523-B38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2133.1987.tb05813.x","article-title":"Retrospective radiographic study of skeletal changes after long-term etretinate therapy","volume":"116","author":"Melnick","year":"1987","journal-title":"Br J Dermatol"},{"key":"2026052522572018500_llaf523-B39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archderm.1996.03890310053007","article-title":"Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris","volume":"132","author":"Margolis","year":"1996","journal-title":"Arch Dermatol"},{"key":"2026052522572018500_llaf523-B40","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2133.1994.tb08524.x","article-title":"Long-term safety of isotretinoin as a treatment for acne vulgaris","volume":"131","author":"Goulden","year":"1994","journal-title":"Br J Dermatol"},{"key":"2026052522572018500_llaf523-B41","first-page":"148","article-title":"The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study","volume":"172","author":"Harms","year":"1986","journal-title":"Dermatologica"},{"key":"2026052522572018500_llaf523-B42","first-page":"240","article-title":"Isotretinoin and acne: a study of relapses","volume":"180","author":"Chivot","year":"1990","journal-title":"Dermatologica"},{"key":"2026052522572018500_llaf523-B43","first-page":"123","article-title":"Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9\u2005years","volume":"186","author":"Lehucher-Ceyrac","year":"1993","journal-title":"Dermatology"},{"key":"2026052522572018500_llaf523-B44","first-page":"15","article-title":"[Acne therapy with isotretinoin in dermatologic practice: a multicenter phase IV study of 788 patients]","volume":"63","author":"Meigel","year":"1988","journal-title":"Z Hautkr"},{"key":"2026052522572018500_llaf523-B45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2133.1997.tb03787.x","article-title":"The effectiveness of acne treatment: an assessment by patients of the outcome of therapy","volume":"137","author":"Newton","year":"1997","journal-title":"Br J Dermatol"},{"key":"2026052522572018500_llaf523-B46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1440-0960.1991.tb00675.x","article-title":"Isotretinoin: cost\u2013benefit study","volume":"32","author":"Lee","year":"1991","journal-title":"Australas J Dermatol"},{"key":"2026052522572018500_llaf523-B47","article-title":"Plane crash revives Accutane questions","author":"Vedantam","year":"10  2002","journal-title":"Washington Post"},{"key":"2026052522572018500_llaf523-B48","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0190-9622(83)80154-6","article-title":"Depression: a side effect of 13-cis-retinoic acid therapy","volume":"9","author":"Hazen","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B49","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archderm.136.10.1231","article-title":"Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide","volume":"136","author":"Jick","year":"2000","journal-title":"Arch Dermatol"},{"key":"2026052522572018500_llaf523-B50","first-page":"18","article-title":"The power of Accutane: the benefits and risks of a breakthrough acne drug","volume":"35","author":"Meadows","year":"2001","journal-title":"FDA Consum"},{"key":"2026052522572018500_llaf523-B51","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1067\/S0190-9622(03)02087-5","article-title":"Isotretinoin and antidepressant pharmacotherapy: a prescription sequence symmetry analysis","volume":"49","author":"Hersom","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B52","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/archderm.141.5.557","article-title":"Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study","volume":"141","author":"Chia","year":"2005","journal-title":"Arch Dermatol"},{"key":"2026052522572018500_llaf523-B53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-4632.2011.05334.x","article-title":"Mood changes, depression and suicide risk during isotretinoin treatment: a prospective study","volume":"52","author":"Nevoralov\u00e1","year":"2013","journal-title":"Int J Dermatol"},{"key":"2026052522572018500_llaf523-B54","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/ije\/dyz093","article-title":"Risk of suicide attempt associated with isotretinoin: a nationwide cohort and nested case-time-control study","volume":"48","author":"Droitcourt","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2026052522572018500_llaf523-B55","first-page":"113","article-title":"Effect of oral isotretinoin on anxiety and depression in patients with acne","volume":"11","author":"Nikam","year":"2020","journal-title":"J Pharmacol Pharmacother"},{"key":"2026052522572018500_llaf523-B56","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40272-019-00340-y","article-title":"Comparison of quality of life, depression, anxiety, suicide, social anxiety and obsessive-compulsive symptoms between adolescents with acne receiving isotretinoin and antibiotics: a prospective, non-\u00adrandomised, open-label study","volume":"21","author":"Erdo\u011fan","year":"2019","journal-title":"Paediatr Drugs"},{"key":"2026052522572018500_llaf523-B57","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jaad.2021.01.107","article-title":"Psychiatric disorders and suicidal behavior in patients with acne prescribed oral antibiotics versus isotretinoin: analysis of a large commercial insurance claims database","volume":"85","author":"Ugonabo","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B58","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jaad.2022.10.031","article-title":"Isotretinoin and the risk of psychiatric disturbances: a global study shedding new light on a debatable story","volume":"88","author":"Kridin","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B59","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.euroneuro.2005.11.006","article-title":"Increased use of mental health services related to isotretinoin treatment: a 5-year analysis","volume":"16","author":"Friedman","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026052522572018500_llaf523-B60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4088\/JCP.10r05993","article-title":"Retinoic acid and affective disorders: the evidence for an association","volume":"73","author":"Bremner","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2026052522572018500_llaf523-B61","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1176\/appi.ajp.162.5.983","article-title":"Functional brain imaging alterations in acne patients treated with isotretinoin","volume":"162","author":"Bremner","year":"2005","journal-title":"Am J Psychiatry"},{"key":"2026052522572018500_llaf523-B62","first-page":"e70502","article-title":"M J. Isotretinoin and suicide: data mining of the United States Food and Drug Administration adverse event reporting system database","volume":"16","author":"Ganjikunta","year":"2024","journal-title":"Cureus"},{"key":"2026052522572018500_llaf523-B63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4088\/JCP.10r05993","article-title":"Retinoic acid and affective disorders: the evidence for an association","volume":"73","author":"Bremner","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2026052522572018500_llaf523-B64","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.det.2005.05.008","article-title":"Acne, depression, and suicide","volume":"23","author":"Hull","year":"2005","journal-title":"Dermatol Clin"},{"key":"2026052522572018500_llaf523-B65","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00213-011-2611-y","article-title":"Influence of isotretinoin on hippocampal-based learning in human subjects","volume":"221","author":"Ormerod","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"2026052522572018500_llaf523-B66","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pnpbp.2007.07.001","article-title":"The neurobiology of retinoic acid in affective disorders","volume":"32","author":"Bremner","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2026052522572018500_llaf523-B67","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/ijd.12169","article-title":"Does isotretinoin therapy of acne cure or cause depression?","volume":"52","author":"Borovaya","year":"2013","journal-title":"Int J Dermatol"},{"key":"2026052522572018500_llaf523-B68","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s13311-021-01168-6","article-title":"Chronic administration of 13-cis-\u00adretinoic acid induces depression-like behavior by altering the activity of dentate granule cells","volume":"19","author":"Su","year":"2022","journal-title":"Neurotherapeutics"},{"key":"2026052522572018500_llaf523-B69","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaad.2016.12.028","article-title":"Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis","volume":"76","author":"Huang","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B70","doi-asserted-by":"crossref","first-page":"e021549","DOI":"10.1136\/bmjopen-2018-021549","article-title":"Use of isotretinoin and risk of depression in patients with acne: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2019","journal-title":"BMJ Open"},{"key":"2026052522572018500_llaf523-B71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jamadermatol.2023.4579","article-title":"Risk of suicide and psychiatric disorders among isotretinoin users: a meta-analysis","volume":"160","author":"Tan","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026052522572018500_llaf523-B72","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0140-6736(83)90538-X","article-title":"Teratogenicity of isotretinoin","volume":"322","author":"Rosa","year":"1983","journal-title":"Lancet"},{"key":"2026052522572018500_llaf523-B73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0890-6238(94)90068-X","article-title":"Use of the retinoid pregnancy prevention program in Canada: patterns of contraception use in women treated with isotretinoin and etretinate","volume":"8","author":"Pastuszak","year":"1994","journal-title":"Reprod Toxicol"},{"key":"2026052522572018500_llaf523-B74","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJM199507133330206","article-title":"A pregnancy-prevention program in women of childbearing age receiving isotretinoin","volume":"333","author":"Mitchell","year":"1995","journal-title":"N Engl J Med"},{"key":"2026052522572018500_llaf523-B75","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/11319190-000000000-00000","article-title":"Isotretinoin use and compliance with the Dutch pregnancy prevention programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data","volume":"33","author":"Teichert","year":"2010","journal-title":"Drug Saf"},{"key":"2026052522572018500_llaf523-B76","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2010.09976.x","article-title":"Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review","volume":"164","author":"Crijns","year":"2011","journal-title":"Br J Dermatol"},{"key":"2026052522572018500_llaf523-B77","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1371\/journal.pmed.0030483","article-title":"What is the best approach to reducing birth defects associated with isotretinoin?","volume":"3","author":"Abroms","year":"2006","journal-title":"PLOS MED"},{"key":"2026052522572018500_llaf523-B78","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archderm.141.5.563","article-title":"Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program","volume":"141","author":"Brinker","year":"2005","journal-title":"Arch Dermatol"},{"key":"2026052522572018500_llaf523-B79","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jaad.2010.09.017","article-title":"The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system","volume":"65","author":"Shin","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B80","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamadermatol.2019.1388","article-title":"US Food and Drug Administration reports of pregnancy and pregnancy-related adverse events associated with isotretinoin","volume":"155","author":"Tkachenko","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026052522572018500_llaf523-B81","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2011.04.006","article-title":"Isotretinoin and iPledge: a view of results","volume":"65","author":"Maloney","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2026052522572018500_llaf523-B82","author":"Health Canada"},{"key":"2026052522572018500_llaf523-B83","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0140-6736(94)92803-7","article-title":"Effects of isotretinoin on male reproductive system","volume":"344","author":"Coleman","year":"1994","journal-title":"Lancet"},{"key":"2026052522572018500_llaf523-B84","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JRS-140617","article-title":"One hundred and twenty cases of enduring sexual dysfunction following treatment","volume":"26","author":"Hogan","year":"2014","journal-title":"Int J Risk Saf Med"},{"key":"2026052522572018500_llaf523-B85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JRS-180744","article-title":"Enduring sexual dysfunction after treatment with antidepressants, 5\u03b1-reductase inhibitors and isotretinoin: 300 cases","volume":"29","author":"Healy","year":"2018","journal-title":"Int J Risk Saf Med"},{"key":"2026052522572018500_llaf523-B86","author":"Medicines and Healthcare products Regulatory Agency. Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido","year":"26  2017","journal-title":"Drug Safety Update"},{"key":"2026052522572018500_llaf523-B87","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/ced\/llae168","article-title":"Exploring the association between isotretinoin and sexual dysfunction: a comprehensive scoping review","volume":"49","author":"Tan","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026052522572018500_llaf523-B88","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ced\/llae249","article-title":"Sexual dysfunction associated with isotretinoin treatment: a survey of the experiences of UK and Irish dermatologists and their approach to counselling and monitoring","volume":"49","author":"Herlihy","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026052522572018500_llaf523-B89","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2025.05.1366","article-title":"No association between isotretinoin and sexual dysfunction in a large retrospective cohort study of acne patients","volume":"93","author":"Neubauer","year":"2025","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf523\/65835846\/llaf523.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/939\/65835846\/llaf523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/939\/65835846\/llaf523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:57:37Z","timestamp":1779764257000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/6\/939\/8377122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":89,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12,11]]},"published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf523","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2025,12,11]]}}}